By using systematic literature reviews sponsors gain vital insights to inform more inclusive, diverse trial designs aligned with FDA DEI guidelines.
Clinical trials must test the efficacy and safety of their treatments on patient populations that are representative of the treatment population1. This is necessary to assess how patients respond to the treatment as different people may experience the same disease differently2. A trial lacking diversity and representativeness results in gaps in our understanding of diseases and conditions and lead to non-generalizable evidence. These factors could potentially lead to suboptimal means to achieve the best possible outcomes at the individual level2,3. Such deficiencies can potentially affect the quality of healthcare decision making, the design of risk-reduction strategies, and the development of optimal medications and interventions2.
The drive to more diverse, equitable and inclusive trials
For these reasons the Food and Drug Administration (FDA) is actively promoting enrollment practices that ensure broader representation in clinical trials. The aim is to reduce bias, promote social justice, improve health equity, and drive scientific innovation2. The National Academies of Science, Engineering, and Medicine (NASEM) have also developed diversity, equity, and inclusion (DEI) guidelines to encourage participation from various demographic groups, including individuals of different genders, races, ethnicities, socioeconomic backgrounds, and more1.
DEI guidelines in practice
Research teams and clinicians are enhancing DEI efforts by adopting DEI guidelines throughout the research timeline from trial design to the regulatory process. The FDA’s proposed strategies suggest reducing patient burden by minimizing study visits, offering financial reimbursements and providing resources in multiple languages4. Community engagement strategies emphasize sponsor collaboration with advocacy groups and holding recruitment events outside of clinical settings. Using telehealth services and flexible visit schedules can address the needs of underrepresented groups such as those living in remote areas or with cognitive impairments.
Using systematic literature reviews to design inclusive trials
An essential element of designing a trial to engage with diverse communities is carrying out a systematic literature review (SLR). Sponsors planning clinical trials can use an SLR to draw insights on the demographics of treatment populations. SLRs can provide details including the incidence, prevalence, risk factors and treatment responses of the relevant disease in different target populations. This comprehensive analysis can identify gaps in representation and provide a foundation to design a more inclusive, representative clinical trial. Used in this way SLRs directly support the FDA’s goal of more diverse clinical trials that better reflect real-world populations. This can ensure that research findings are generalizable across different communities.
The FDA’s guidance documents provide a comprehensive framework for sponsors to create inclusive, participant-centric trial designs that engage diverse communities while reducing participant burdens4. SLRs are an essential element of this framework, offering data-driven insights that inform the development of more inclusive trials. By enabling detailed assessments of treatment efficacy and safety across diverse populations, SLRs contribute to more equitable and impactful clinical research practices.
Conclusion
Ensuring that clinical trial patients are diverse and reflect the real world patient populations is critical to demonstrate the safety and effectiveness of the proposed treatment. Many trial design factors contribute to attracting a more diverse patient cohort to a study, including decentralising trials, reimbursing patients’ trial-related expenses and translating communications into multiple languages. SLRs can provide sponsors with vital insights to inform their trial design to ensure a diverse patient cohort that accurately represents the treatment population.
At ICON Health Economics & Epidemiology, we have a broad range of expertise to support diversity and equity planning in clinical trials. One such expertise lies in conducting these literature reviews to help understand the demographics of a treatment population. At a minimum such reviews can inform the incidence, prevalence, risk factors, and treatment response of a disease with details of distribution within a geographical region to provide the basis for designing clinical trials.
By: Immaculate Nevis MD, MBA, PhD & Liliane Martinez MD, MSc, ICON Insights, Evidence & Value
References:
1 Stacey Versavel et al 2023. Diversity, equity, and inclusion in clinical trials: A practical guide from the perspective of a trial sponsor. Contemporary Clinical Trials.
2 NIH Gov Resources. The importance of Diversity and Inclusion in Clinical Trials.
3 Vindell Washington et al 2022. Diversity, Equity, and Inclusion in Clinical Research: A Path Toward Precision Health for Everyone. Clinical Pharmacology and Therapeutics.
In this section
-
Digital Disruption
-
Digital Disruption whitepaper
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Digital Disruption whitepaper
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel